The White House withdrew Heidi Overton’s nomination to lead the U.S. Food and Drug Administration, adding uncertainty to an agency already operating without a confirmed permanent commissioner. Analysts said the change is unlikely to immediately disrupt day-to-day operations, but it heightens scrutiny over who will set priorities for drug review policy, user fee reauthorization, and the FDA’s approach to emerging tools in science. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) announced it will begin accepting certain trial applications that rely on non-OECD preclinical safety data for serious diseases where patients lack other treatment options. OECD-generated data remains the preferred standard overall, while MHRA plans risk-based inspections of frequently used non-OECD test facilities. Taken together, the two developments point to a near-term governance and evidence-access reset—one focused on leadership continuity at the FDA and another on regulatory flexibility for globalized nonclinical data packages in early-stage development.